Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report
Abstract Advanced thymic carcinomas have limited treatment options. Recently, lenvatinib was approved for advanced thymic carcinoma treatment. However, the clinical benefit of lenvatinib re‐administration in patients with advanced thymic carcinoma who developed prior lenvatinib treatment resistance...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-12-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14699 |
| _version_ | 1797987401412378624 |
|---|---|
| author | Yuto Terashima Taiki Hakozaki Susumu Takeuchi Yukio Hosomi |
| author_facet | Yuto Terashima Taiki Hakozaki Susumu Takeuchi Yukio Hosomi |
| author_sort | Yuto Terashima |
| collection | DOAJ |
| description | Abstract Advanced thymic carcinomas have limited treatment options. Recently, lenvatinib was approved for advanced thymic carcinoma treatment. However, the clinical benefit of lenvatinib re‐administration in patients with advanced thymic carcinoma who developed prior lenvatinib treatment resistance (lenvatinib rechallenge) remains unclear. Here, we present a case treated with lenvatinib rechallenge for advanced thymic carcinoma who was previously treated with lenvatinib as the second‐line treatment followed by multiple cytotoxic agents. Disease control rapidly deteriorated after the eighth line of treatment because of uncontrollable right pleural and pericardial effusion, which required repeated thoracic and pericardial drainage. Shortly after lenvatinib re‐administration, rapid pleural and pericardial effusion reduction was observed. Thereafter, the patient achieved sustained clinical response with good pleural and pericardial effusion control for approximately 7 months. Our case might suggest lenvatinib rechallenge as a treatment option for patients with advanced thymic carcinoma, especially those with poor pleural and pericardial effusion control. |
| first_indexed | 2024-04-11T07:48:04Z |
| format | Article |
| id | doaj.art-2c1f348c98ca40058bd1080baa3627ff |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-11T07:48:04Z |
| publishDate | 2022-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-2c1f348c98ca40058bd1080baa3627ff2022-12-22T04:36:11ZengWileyThoracic Cancer1759-77061759-77142022-12-0113233408341110.1111/1759-7714.14699Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case reportYuto Terashima0Taiki Hakozaki1Susumu Takeuchi2Yukio Hosomi3Department of Thoracic Oncology and Respiratory Medicine Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Thoracic Oncology and Respiratory Medicine Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Pulmonary Medicine and Oncology Graduate School of Medicine, Nippon Medical School Tokyo JapanDepartment of Thoracic Oncology and Respiratory Medicine Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanAbstract Advanced thymic carcinomas have limited treatment options. Recently, lenvatinib was approved for advanced thymic carcinoma treatment. However, the clinical benefit of lenvatinib re‐administration in patients with advanced thymic carcinoma who developed prior lenvatinib treatment resistance (lenvatinib rechallenge) remains unclear. Here, we present a case treated with lenvatinib rechallenge for advanced thymic carcinoma who was previously treated with lenvatinib as the second‐line treatment followed by multiple cytotoxic agents. Disease control rapidly deteriorated after the eighth line of treatment because of uncontrollable right pleural and pericardial effusion, which required repeated thoracic and pericardial drainage. Shortly after lenvatinib re‐administration, rapid pleural and pericardial effusion reduction was observed. Thereafter, the patient achieved sustained clinical response with good pleural and pericardial effusion control for approximately 7 months. Our case might suggest lenvatinib rechallenge as a treatment option for patients with advanced thymic carcinoma, especially those with poor pleural and pericardial effusion control.https://doi.org/10.1111/1759-7714.14699lenvatinibpericardial effusionpleural effusionrechallengethymic carcinoma |
| spellingShingle | Yuto Terashima Taiki Hakozaki Susumu Takeuchi Yukio Hosomi Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report Thoracic Cancer lenvatinib pericardial effusion pleural effusion rechallenge thymic carcinoma |
| title | Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report |
| title_full | Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report |
| title_fullStr | Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report |
| title_full_unstemmed | Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report |
| title_short | Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report |
| title_sort | lenvatinib rechallenge in a patient with advanced thymic carcinoma a case report |
| topic | lenvatinib pericardial effusion pleural effusion rechallenge thymic carcinoma |
| url | https://doi.org/10.1111/1759-7714.14699 |
| work_keys_str_mv | AT yutoterashima lenvatinibrechallengeinapatientwithadvancedthymiccarcinomaacasereport AT taikihakozaki lenvatinibrechallengeinapatientwithadvancedthymiccarcinomaacasereport AT susumutakeuchi lenvatinibrechallengeinapatientwithadvancedthymiccarcinomaacasereport AT yukiohosomi lenvatinibrechallengeinapatientwithadvancedthymiccarcinomaacasereport |